DK1255537T3 - Farnesylproteintransferasehæmmere til behandling af brystcancer - Google Patents

Farnesylproteintransferasehæmmere til behandling af brystcancer

Info

Publication number
DK1255537T3
DK1255537T3 DK01905717T DK01905717T DK1255537T3 DK 1255537 T3 DK1255537 T3 DK 1255537T3 DK 01905717 T DK01905717 T DK 01905717T DK 01905717 T DK01905717 T DK 01905717T DK 1255537 T3 DK1255537 T3 DK 1255537T3
Authority
DK
Denmark
Prior art keywords
breast cancer
protein transferase
treatment
transferase inhibitors
farnesyl protein
Prior art date
Application number
DK01905717T
Other languages
Danish (da)
English (en)
Inventor
Peter Albert Palmer
Ivan David Horak
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of DK1255537T3 publication Critical patent/DK1255537T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK01905717T 2000-02-04 2001-02-01 Farnesylproteintransferasehæmmere til behandling af brystcancer DK1255537T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00200373 2000-02-04

Publications (1)

Publication Number Publication Date
DK1255537T3 true DK1255537T3 (da) 2006-08-21

Family

ID=8170976

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01905717T DK1255537T3 (da) 2000-02-04 2001-02-01 Farnesylproteintransferasehæmmere til behandling af brystcancer

Country Status (13)

Country Link
US (4) US20030027839A1 (https=)
EP (1) EP1255537B1 (https=)
JP (1) JP5491681B2 (https=)
AT (1) ATE323474T1 (https=)
AU (1) AU2001233726A1 (https=)
CA (1) CA2396865C (https=)
CY (1) CY1105477T1 (https=)
DE (1) DE60118889T2 (https=)
DK (1) DK1255537T3 (https=)
ES (1) ES2262626T3 (https=)
PT (1) PT1255537E (https=)
SI (1) SI1255537T1 (https=)
WO (1) WO2001056552A2 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7342016B2 (en) 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
DE60230017D1 (de) * 2001-02-15 2009-01-08 Janssen Pharmaceutica Nv Farnesyl-protein-transferase hemmer in kombination mit antiöstrogenen
WO2003047697A2 (en) * 2001-11-30 2003-06-12 Schering Corporation Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer
US7102251B2 (en) * 2003-08-22 2006-09-05 Distributed Power, Inc. Bi-directional multi-port inverter with high frequency link transformer
JP2007510661A (ja) * 2003-11-06 2007-04-26 シェーリング　コーポレイション 乳癌の治療のための、ファルネシルトランスフェラーゼインヒビターと抗ホルモン剤との組合せ
RU2006124843A (ru) 2003-12-12 2008-01-20 Уайт (Us) Хинолины, пригодные для лечения сердечно-сосудистого заболевания
US20060106060A1 (en) * 2004-03-18 2006-05-18 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies (Lansbury)
US20050272722A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
CA2559282A1 (en) * 2004-03-18 2005-09-29 Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
WO2005089518A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Uch-l1 expression and cancer therapy
CA2559285A1 (en) * 2004-03-18 2005-09-29 Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
US20060194821A1 (en) * 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
EP1968591A4 (en) 2005-12-23 2010-02-17 Link Medicine Corp TREATMENT OF SYNUCLEINOPATHIES
WO2009151683A2 (en) * 2008-03-12 2009-12-17 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
JP2012508768A (ja) * 2008-11-13 2012-04-12 リンク・メディスン・コーポレーション アザキノリノン誘導体及びその使用
EP2288195B1 (en) * 2009-08-20 2019-10-23 Samsung Electronics Co., Ltd. Method and apparatus for operating a base station in a wireless communication system
CA2888485C (en) 2012-10-16 2021-01-26 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of ror.gamma.t
MY189505A (en) 2012-10-16 2022-02-16 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of roryt
ES2619610T3 (es) 2012-10-16 2017-06-26 Janssen Pharmaceutica Nv Moduladores de ROR-gamma-t de quinolinilo enlazado con heteroarilo
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
BR112016008215A2 (pt) 2013-10-15 2017-09-26 Janssen Pharmaceutica Nv moduladores de quinolinila ligados por alquila de roryt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
ES2742843T3 (es) 2013-10-15 2020-02-17 Janssen Pharmaceutica Nv Moduladores de quinolinilo de ROR(gamma)t
HUE044698T2 (hu) 2015-08-17 2019-11-28 Kura Oncology Inc Kezelési módszer rákos páciensek kezelésére farnezil-transzferáz inhibitorokkal
JP2019534290A (ja) 2016-11-03 2019-11-28 クラ オンコロジー， インコーポレイテッド 癌の治療方法において使用するためのファルネシルトランスフェラーゼ阻害剤

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69620445T2 (de) * 1995-12-08 2002-12-12 Janssen Pharmaceutica N.V., Beerse (imidazol-5-yl)methyl-2-chinolinoderivate als farnesyl protein transferase inhibitoren
US5874442A (en) * 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
US5994364A (en) * 1996-09-13 1999-11-30 Schering Corporation Tricyclic antitumor farnesyl protein transferase inhibitors
TW591030B (en) * 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
RU2205831C2 (ru) * 1997-04-25 2003-06-10 Янссен Фармацевтика Н.В. Хиназолиноны, ингибирующие фарнезилтрансферазу
US5925639A (en) * 1997-06-17 1999-07-20 Schering Corporation Keto amide derivatives useful as farnesyl protein transferase inhibitors
US5852034A (en) * 1997-06-17 1998-12-22 Schering Corporation Benzo(5,6)cycloheptapyridine cyclic ureas and lactams useful as farnesyl protein transferase inhibitors
US6096757A (en) * 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
WO2000001701A1 (en) * 1998-07-02 2000-01-13 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
PL193464B1 (pl) * 1998-07-06 2007-02-28 Janssen Pharmaceutica Nv Zastosowanie inhibitora białkowej transferazy farnezylowej
DE69923849T2 (de) * 1998-08-27 2006-01-12 Pfizer Products Inc., Groton Quinolin-2-on-derivate verwendbar als antikrebsmittel
DK1140935T3 (da) * 1998-12-23 2003-09-01 Janssen Pharmaceutica Nv 1,2-anellerede quinolinderivater
AU2292801A (en) * 1999-12-22 2001-07-03 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Compositions and methods for treatment of breast cancer
ATE375794T1 (de) * 2000-02-24 2007-11-15 Janssen Pharmaceutica Nv Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebs
WO2001064252A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
US20020022633A1 (en) * 2000-06-30 2002-02-21 Williams Theresa M. Inhibitors of prenyl-protein transferase

Also Published As

Publication number Publication date
US20040192726A1 (en) 2004-09-30
WO2001056552A3 (en) 2002-04-25
WO2001056552A2 (en) 2001-08-09
US20110098318A1 (en) 2011-04-28
US20030027839A1 (en) 2003-02-06
ES2262626T3 (es) 2006-12-01
DE60118889T2 (de) 2006-11-30
AU2001233726A1 (en) 2001-08-14
DE60118889D1 (de) 2006-05-24
JP5491681B2 (ja) 2014-05-14
CA2396865C (en) 2009-04-14
CY1105477T1 (el) 2010-04-28
US20090018164A1 (en) 2009-01-15
JP2003521509A (ja) 2003-07-15
CA2396865A1 (en) 2001-08-09
EP1255537B1 (en) 2006-04-19
PT1255537E (pt) 2006-09-29
SI1255537T1 (sl) 2006-10-31
ATE323474T1 (de) 2006-05-15
EP1255537A2 (en) 2002-11-13

Similar Documents

Publication Publication Date Title
DK1255537T3 (da) Farnesylproteintransferasehæmmere til behandling af brystcancer
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
DK1648905T3 (da) Inhibitorer for thienopyridin- og furopyridinkinase
ATE375794T1 (de) Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebs
PL406680A1 (pl) Inhibitory kinaz tyrozynowych
DK1519724T3 (da) Fredericamycin-derivater som lægemidler til behandling af tumorer
ATE554087T1 (de) Neue kinaseinhibitoren
DE60014873D1 (de) Synergistische zusammensetzungen zur krebsbehandlung
BG66084B1 (bg) Циклопентаноиндоли, състави,съдържащи такива съединения и използването им
BRPI0417708A (pt) derivados organofosfóricos dos indazóis e sua utilização como inibidores das proteìnas quinases
DK1272188T3 (da) Anvendelse af EGFR-tyrosinkinaseinhibitorer til behandling af brystcancer
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
DK1339407T3 (da) Farnesylproteintransferaseinhibitorer til behandling af inflammatorisk tarmsygdom
BRPI0410669A (pt) inibidores de caspase e usos dos mesmo
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
DK1315506T3 (da) Phospholipidderivater af valproinsyre og blandinger deraf
IL153680A0 (en) Aplidine derivatives and methods for the preparation thereof
DE60233261D1 (de) Inhibitoren von humanem adam-10
DE60329326D1 (de) Tace inhibitoren
MXPA04005809A (es) Inhibidores de proteinas quinasas.
MXPA03005374A (es) Carbazoles antitumorales.
UY26911A1 (es) Ácidos amino (oxo) acéticos inhibidores de la proteina tirosina fosfatasa
ATE267194T1 (de) Medikamente geeignet zur behandlung von proliferativen erkrankungen
ATE536874T1 (de) Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen
DE60334289D1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen